Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Cessation of coverage

Percheron Therapeutics
3:27pm
February 7, 2025
PER recently released its 2Q report showing a closing cash balance of A$17.4m as at the end of December. Key new information in the report was an estimated trial closure cost estimate of between A$6-7m in line with our expectations. Costs for trial closure and ongoing administrative operating cost burn will be partially offset by R&D rebates. Considering PER’s cash balance and the expected inbound/outbound cash costs ahead, our prior expectations of A$10m of cash balance remaining looks about right on a 12-month forward view, which equates to ~1 cps in value. As highlighted in our topline result note, we held limited hope of PER’s post-hoc analyses bearing significant sub-group clinical utility given the presented topline results other than providing context. The updated data presented subsequently has reconfirmed this, with the drug having the expected pharmacological response however failing to show any meaningful effect on the outcome measures. Potential hypotheses range from the dose being too low, alternative disease mechanisms overpowered the benefit of suppressing CDd+ lymphocytes, to the endpoints being too insensitive to detect a treatment effect. In any case, PER has effectively ‘closed the book’ on avicursen development. The result is a company shell with limited asset value outside of cash backing minus expected outflows. As with most listed shells, we would expect a new asset to be brought forward in time to utilize the residual value of the corporate entity and cash balance however highlight the value outside of cash backing post contractual obligations should be made on a case-by-case basis if and when a new direction surfaces. Given the limited information and unknowns with a likely change of direction, we discontinue coverage of Percheron Therapeutics (PER AU). Our forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Hard to fault

REA Group
3:27pm
February 6, 2025
REA’s 1H25 result was a small beat versus consensus across most key metrics. Operationally, the group reported strong revenue growth in its major business segments, i.e Australia Residential, (+21% on pcp) and REA India (+46% on pcp). REA reiterated its expectations for double-digit yield growth for FY25, and noted that whilst volumes were resilient in the first half, the 2H has the business cycling some strong listings volume in the pcp. In what was arguably a surprise, CEO Owen Wilson announced his intention to retire. Group EBITDA estimates across FY25-FY27 remain largely unchanged (-~0.5-1%). Our DCF-derived price target rises to A$2 (from A$215) with the above changes offset by a valuation roll-forward. However, at ~29x FY26F EV/EBITDA, REA is trading 1 standard deviation rich versus its 10 year average. Hold maintained.

Market confidence still swinging wildly

Beach Energy
3:27pm
February 6, 2025
BPT has been on an interesting ride, it gives the impression of the street regularly finding new reasons to be bullish on the stock ahead of the next downgrade. This seemed at play once again with BPT rallying hard post its December Perth Basin site visit ahead of a somewhat disappointing 1H25 update. A largely in line 1H25 result, with a dividend miss, continued troubles at Waitsia, narrowed FY25 guidance that could trigger consensus downgrades, and capex skew that puts pressure on 2H FCF generation. Post the recent rally and entering a tougher 2H with still some important questions to answer, we pullback our recommendation to Hold (from Add).

Tracking well but all eyes will be on the Berry deal

Amcor
3:27pm
February 5, 2025
AMC’s 1H25 result on a constant currency basis was in line with expectations with management reiterating guidance for the full year. Key positives: Volumes continued to improve sequentially; EBIT margin was higher in both Flexibles (+30bp to 12.9%) and Rigid Packaging (+70bp to 7.3%) supported by cost-out and restructuring benefits; ROFE increased 50bp to 15.0%. Key negative: Ongoing destocking in the healthcare sector once again had a negative impact on price/mix, although management said this has now largely run its course with volumes expected to improve in 2H25. AMC said the merger with Berry Global is on track with the respective shareholder meetings to take place on 25 February. We make minimal changes to earnings forecasts. However, a roll-forward of our model to FY26 forecasts and updates to FX (particularly a lower AUD/USD) see our target price rise to $16.45 (from $15.75). Hold rating maintained.

International flywheel coming to life

Pinnacle Investment Mgmt
3:27pm
February 5, 2025
PNI delivered 1H25 NPAT of A$75.7m, up 150% on pcp. Affiliate earnings grew 100% to A$74.3m; and 52% to A$37.9m excluding performance fees (PF). Half-on-half, Affiliate earnings (ex-performance fees) grew 9.6%; and group core earnings (ex PF and principal investments) grew +8.4% (pre-tax) to A$30.4m. Group FUM closed at A$155.4bn, +41% for the half (+16% ex-acquisitions). FUM growth comprised acquisitions A$27.9bn; inflows A$6.7bn; performance A$10.7bn. 2H25 expectations are supported by ~6% higher starting FUM (pre acquisitions); acquisition contributions; and typical 2H earnings skews in certain managers. Medium-term ‘embedded’ drivers are visible from the scaling of several managers; and the long-term offshore opportunity is significant. PNI is arguably expensive on near-term valuation multiples (susceptible to short-term volatility), however we see embedded strong growth medium term; the operating structure is now expanded to facilitate ongoing offshore growth; and near-term catalysts look supportive (accelerating flows CY25; acquisitions).

Rigs to riches

Vysarn
3:27pm
February 4, 2025
We initiate on Vysarn (VYS) with a Speculative Buy rating and a 55cps target price. VYS is a well-led, diversified, high margin (>10% NPAT), integrated water services provider with significant growth prospects and a strong balance sheet (net cash). We forecast EPS growth of +14% and +25% in FY25 and FY26, respectively. For FY26, we believe earnings risk is skewed to the upside if the company can replicate past performance by accelerating growth for recently acquired businesses. In our view, the core business (all divisions except Vysarn Asset Management) underpins a valuation of 46cps, which means at the current share price the more speculative asset management business comes as a free option.

4Q24 Quarterly Update

Frontier Digital Ventures
3:27pm
February 4, 2025
FDV’s 4Q24 update was relatively soft overall, in our view, with both revenue and EBITDA growth being impacted by tough operating conditions, and a restructure of the InfoCasas transaction model. FDV’s fundamental problem at the moment in our view, is it is not growing with group Revenue and EBITDA largely stagnant during FY22-FY24.  The LATAM strategic review may unlock value, but headwinds in this business unit may also limit upside from this review. We lower FDV FY24F/FY25F EPS by ~5% to >10% (off low bases) on softer revenue growth and EBITDA margin assumptions near term. Our PT is reduced to A$0. (previously A$0.61). We think there is clearly long-term value in FDV given its assembled portfolio, and hence we maintain our ADD call, but we acknowledge the market needs to see evidence of momentum before FDV re-rates.

Patience to yield rewards

Mitchell Services
3:27pm
February 4, 2025
2Q financials fell below our expectations, primarily as MSV’s build-up into new contracts and capabilities has stepped up more quickly than expected. We trim our FY25 forecasts/valuation to reflect the delay to higher rig utilisation. FY25 performance and dividends have been crimped by MSV’s current ‘transition period’. However, FY26 looks strongly set up for higher earnings, cash conversion/ release and higher dividends/ returns. MSV remains too cheap on all value measures and suits patient investors.

Major clinical trials to read out soon – key inflection point

Opthea
3:27pm
February 3, 2025
Opthea (OPT) is a biopharmaceutical company developing a potential treatment for wet age-related macular degeneration (wet AMD), a serious eye condition effecting 3.1m people in the US and Europe. The existing market for current treatments is estimated by management at US$15bn. Two major clinical trials are due to read out within the next 6 months and if successful, approval in the US is anticipated in 2HCY26. Consensus has a target price of A$2.07 compared with the current price of $1.07. We have prepared a brief note outlining the upcoming clinical trials and timelines noting the near-term catalysts are binary and appropriate for investors with a higher risk profile.

International Spotlight

General Motors Company
3:27pm
February 3, 2025
General Motors Company (GM-US), headquartered in Detroit, is a global automotive company known for brands like Chevrolet and Cadillac, offering a diverse portfolio of vehicles. A market leader with considerable scale, GM has global operations and employs over 165,000 staff worldwide.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more